Drug Trial Radar · NCT07254806
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
162
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Nov 24, 2027
Study completion Nov 24, 2028
Sponsor
- Lead sponsor
- DiscGenics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks). The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening. Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham. Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date. Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio. * IDCT (n=108) * Sham (n=54)
Conditions
- Degenerative Disc Disease
Interventions
IDCT (rebonuputemcel)Biological
Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc.
Sham (No Treatment)Other
Single Sham needle insertion up to the annulus of a single target disc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual Analogue Scale (VAS) for low back painTime frame: Week 52
- Oswestry Disability Index (ODI)Time frame: Week 52
- Adverse EventsTime frame: Day 1 to Week 52 in each treatment group.
- Adverse events of special interestTime frame: Day 1 to Week 52 in each treatment group
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics
Birmingham, Alabama · Recruiting
Mayo Clinic (AZ)
Phoenix, Arizona · Recruiting
HonorHealth
Scottsdale, Arizona · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Solaris Research Institute
San Diego, California · Recruiting
Source Healthcare
Santa Monica, California · Recruiting
Pain Management and Injury Relief
Thousand Oaks, California · Recruiting
International Spine, Pain and Performance Center
Washington D.C., District of Columbia · Recruiting
Mayo Clinic (FL)
Jacksonville, Florida · Recruiting
University of Miami Health System
Miami, Florida · Recruiting
Conquest Research
Orlando, Florida · Recruiting
Vantage Clinical Trials
St. Petersburg, Florida · Recruiting
Vantage Clinical Trials
Tampa, Florida · Recruiting
Injury Care Family Care Research
Boise, Idaho · Terminated
Axis Spine Center
Post Falls, Idaho · Recruiting
Rush University Medical Center
Chicago, Illinois · Recruiting
Indiana Spine Group
Carmel, Indiana · Recruiting
Norton Leatherman Spine Center
Louisville, Kentucky · Recruiting
Ochsner Health System
New Orleans, Louisiana · Recruiting
Mayo Clinic (MN)
Rochester, Minnesota · Recruiting
The Orthopedic Center of St. Louis
St Louis, Missouri · Recruiting
Weill Cornell Medicine for Comprehensive Spine Care
New York, New York · Recruiting
Wake Research
Wilmington, North Carolina · Recruiting
Carolinas Pain Institute/ Center For Clinical Research
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Pacific Sports and Spine
Eugene, Oregon · Recruiting
Main Line Spine
King of Prussia, Pennsylvania · Recruiting
Semmes Murphey Neurological Clinic
Memphis, Tennessee · Recruiting
Pain Specialists of America
Austin, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Virginia iSpine Physicians
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.